Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PDL1 t haNK - ImmunityBio

Next Previous
Drug Profile

PDL1 t haNK - ImmunityBio

Alternative Names: PD-L1 T-haNK; PD-L1 targeted high-affinity natural killer cells - ImmunityBio; PD-L1.t-haNK; t-haNK™ Cells; t‑haNK®

Latest Information Update: 31 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NantKwest
  • Developer ImmunityBio
  • Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastric cancer; Glioblastoma; Pancreatic cancer; Solid tumours; Squamous cell cancer
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 17 Jul 2024 Phase-II clinical trials in Glioblastoma (Second-line therapy or greater, Combination therapy) in USA (IV) (NCT06061809)
  • 25 Sep 2023 ImmunityBio plans a phase II trial for Glioblastoma(Recurrent, Second-line therapy or greater, Combination therapy) in November 2023 (IV) (NCT06061809)
  • 19 Jan 2023 Updated efficacy data from a phase II QUILT-88 trial in Pancreatic cancer released by ImmunityBio

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top